Epilepsy Phenome/Genome Project

Premier Research and CENTOGENE Launch Strategic Partnership to Accelerate and De-Risk Rare Disease Clinical Development

Retrieved on: 
Monday, January 9, 2023
Epigenomics, Partnership, Drug discovery, Metabolomics, CLIA, Disease, Research, Patient, Degenerative disease, Physician, Therapy, Epilepsy Phenome/Genome Project, CAP, History, CNTG, ISO, Neurodegeneration, Pharmaceutical industry, Proteomics

MORRISVILLE, N.C., and CAMBRIDGE, Mass., ROSTOCK, Germany, and BERLIN, Jan. 9, 2023 /PRNewswire/ -- Premier Research, whose mission is to help the most innovative biotech and medtech companies take their best ideas from concept to commercialization, and Centogene N.V. [Nasdaq: CNTG], the essential life science partner for data-driven answers in rare and neurodegenerative diseases, have announced a strategic partnership to provide end-to-end support in rare disease clinical trials. The collaboration aims to improve patient identification, stratification, recruitment, and enrollment, thereby increasing the likelihood of study success.

Key Points: 
  • Inherently small patient populations coupled with the complexities of disease diagnosis create significant challenges in enrolling rare disease clinical trial participants.
  • Combining Premier Research's deep expertise in rare disease product development with advanced insights generated from the CENTOGENE Biodatabank and multiomic reference laboratories will support the faster identification of eligible patients.
  • "The CENTOGENE Biodatabank and multiomic-based services will enhance how we design and recruit for rare disease clinical trials," Premier Research Senior Vice President, Project Delivery Angi Robinson said.
  • With extensive experience based on more than 240 rare disease studies in the past five years, Premier Research is constantly investing in new approaches that meet the complexities of rare disease research.

CENTOGENE Receives Nasdaq Non-Compliance Notice

Retrieved on: 
Friday, December 16, 2022
Physician, Diagnosis, Drug discovery, Epilepsy Phenome/Genome Project, Failure, Nature, Security (finance), Food, Instability, CAP, Regulation of tobacco by the U.S. Food and Drug Administration, CLIA, Epigenomics, Risk, Legislation, Calendar, Neurodegeneration, Metabolomics, Growth, ISO, Precision medicine, Patient, Pharmaceutical industry, Proteomics

These notifications do not impact the Company’s listing on the Nasdaq Global Market at this time.

Key Points: 
  • These notifications do not impact the Company’s listing on the Nasdaq Global Market at this time.
  • We integrate multiomic technologies with the CENTOGENE Biodatabank – providing dimensional analysis to guide the next generation of precision medicine.
  • Since our founding in 2006, CENTOGENE has been offering rapid and reliable diagnosis – building a network of approximately 30,000 active physicians.
  • To date, the CENTOGENE Biodatabank has contributed to generating novel insights for more than 260 peer-reviewed publications.

CENTOGENE to Participate in Upcoming Conferences in December

Retrieved on: 
Thursday, December 1, 2022
Growth, Diagnosis, Nature, Food, Physician, Instability, Patient, Regulation of tobacco by the U.S. Food and Drug Administration, Legislation, Epilepsy Phenome/Genome Project, Epigenomics, CLIA, Security (finance), Neurodegeneration, Metabolomics, Precision medicine, Risk, ISO, CAP, Drug discovery, Pharmaceutical industry, Proteomics

CENTOGENEs mission is to provide data-driven, life-changing answers to patients, physicians, and pharma companies for rare and neurodegenerative diseases.

Key Points: 
  • CENTOGENEs mission is to provide data-driven, life-changing answers to patients, physicians, and pharma companies for rare and neurodegenerative diseases.
  • We integrate multiomic technologies with the CENTOGENE Biodatabank providing dimensional analysis to guide the next generation of precision medicine.
  • Since our founding in 2006, CENTOGENE has been offering rapid and reliable diagnosis building a network of approximately 30,000 active physicians.
  • To date, the CENTOGENE Biodatabank has contributed to generating novel insights for more than 260 peer-reviewed publications.

CENTOGENE Announces Changes to Supervisory Board, Including Appointment of Mary Sheahan

Retrieved on: 
Monday, November 21, 2022
Growth, CFO, Diagnosis, Financial management, Nature, Science, Food, Physician, Instability, Patient, Regulation of tobacco by the U.S. Food and Drug Administration, Neurology, Legislation, IPO, Mass meeting, Epilepsy Phenome/Genome Project, Élan, CLIA, Epigenomics, Security (finance), Neurodegeneration, Metabolomics, Supervisory board, KPMG, Precision medicine, Risk, Audit committee, ISO, CAP, Drug discovery, Property management, Pharmaceutical industry, Proteomics

Ms. Sheahan will serve as a member ad interim of the Companys Supervisory Board starting December 1, 2022.

Key Points: 
  • Ms. Sheahan will serve as a member ad interim of the Companys Supervisory Board starting December 1, 2022.
  • It is also planned that Ms. Sheahan will assume the role of Chair of the Audit Committee.
  • Ms. Sheahan currently serves as CFO of Avillion LLP, a private equity-backed life sciences company focused on the co-development and financing of pharmaceutical products.
  • We are very pleased to welcome Ms. Sheahan as a new member of the Supervisory Board, stated Peer Schatz, Chairman of the Supervisory Board of CENTOGENE.

CENTOGENE to Participate in Upcoming Conferences in November

Retrieved on: 
Thursday, November 10, 2022
CLIA, Nature, U.S. Securities and Exchange Commission, CAP, Food, Risk, Diagnosis, Drug discovery, Epilepsy Phenome/Genome Project, Legislation, Regulation of tobacco by the U.S. Food and Drug Administration, Precision medicine, SEC, ISO, Conference, Patient, Physician, Growth, Epigenomics, Security (finance), Metabolomics, Instability, Industry, Neurodegeneration, Pharmaceutical industry, Proteomics

CENTOGENEs mission is to provide data-driven, life-changing answers to patients, physicians, and pharma companies for rare and neurodegenerative diseases.

Key Points: 
  • CENTOGENEs mission is to provide data-driven, life-changing answers to patients, physicians, and pharma companies for rare and neurodegenerative diseases.
  • We integrate multiomic technologies with the CENTOGENE Biodatabank providing dimensional analysis to guide the next generation of precision medicine.
  • Since our founding in 2006, CENTOGENE has been offering rapid and reliable diagnosis building a network of approximately 30,000 active physicians.
  • To date, the CENTOGENE Biodatabank has contributed to generating novel insights for more than 260 peer-reviewed publications.

CENTOGENE Launches Rare and Neurodegenerative Disease Biodata Network

Retrieved on: 
Thursday, November 3, 2022
Precision medicine, Company, Research, Therapy, Growth, MIT, Hospital, Food, GDPR, Risk, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Industry, GLOBE, FDA, BC, Legislation, Epilepsy Phenome/Genome Project, Nasdaq, CAP, Data analysis, Nature, CEO, Metabolomics, Physician, ISO, U.S. Securities and Exchange Commission, CLIA, Data, Medicine, Privacy, Acceleration, Partnership, R, Technology, Pharmacy, Security (finance), Epigenomics, SEC, Drug discovery, Diagnosis, Patient, Neurodegeneration, Solution, Pharmaceutical industry, Medical device, Risk management, Proteomics

and ROSTOCK, Germany and BERLIN, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the global launch of its Biodata Network, a portfolio of data-driven partnering solutions, including Biodata Licenses and Insight Reports, for biopharma and research institutions.

Key Points: 
  • and ROSTOCK, Germany and BERLIN, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the global launch of its Biodata Network, a portfolio of data-driven partnering solutions, including Biodata Licenses and Insight Reports, for biopharma and research institutions.
  • At CENTOGENE, we are committed to delivering data-driven, life-changing answers to accelerate and de-risk drug discovery, development, and commercialization, said Kim Stratton, Chief Executive Officer at CENTOGENE.
  • Ultimately, we want to heal the world of rare and neurodegenerative diseases, and we believe offering greater access to the CENTOGENE Biodatabank will accelerate bringing potentially life-saving therapeutics to patients around the world.
  • Since our founding in 2006, CENTOGENE has been offering rapid and reliable diagnosis building a network of approximately 30,000 active physicians.

Epilepsy Community Calls for Rescission of Six Protected Classes Demonstration and Protection of Access to Anticonvulsants

Retrieved on: 
Tuesday, February 2, 2021
Clinical medicine, Epilepsy, Health, Medicine, Seizure, Anticonvulsant, Epilepsy Phenome/Genome Project, Orrin Devinsky

Epilepsy is a spectrum condition with a wide range of seizure types and seizure control varying from person to person.

Key Points: 
  • Epilepsy is a spectrum condition with a wide range of seizure types and seizure control varying from person to person.
  • With advances in genetics, imaging, and mechanistic understanding, a growing number of people are known to have a rare form of epilepsy.
  • "Given its complex nature, epilepsy medications are not interchangeable," said Dr. Jacqueline French, Chief Medical and Innovation Officer, Epilepsy Foundation; and Professor, Comprehensive Epilepsy Center, NYU Langone Health.
  • "Allowing Part D plans to so drastically restrict coverage of anticonvulsants is dangerous and potentially life-threatening for people with the epilepsies."

Focal Epilepsy Often Overlooked

Retrieved on: 
Tuesday, October 20, 2020
Seizure types, Health, Epilepsy, Clinical medicine, Neurology, Focal seizure, Medicine, Epilepsy Phenome/Genome Project, Epilepsy syndromes

The study, publishing online Oct. 20 in the journal Epilepsia, addressed focal epilepsy, the most common form of this brain disorder.

Key Points: 
  • The study, publishing online Oct. 20 in the journal Epilepsia, addressed focal epilepsy, the most common form of this brain disorder.
  • "Our study highlights how common the early and subtle signs of focal epilepsy are," says study senior investigator Jaqueline A. French, MD, a professor of neurology and director of translational research and clinical trials for epilepsy at NYU Langone Health.
  • The World Health Organization estimates that at least 50 million people worldwide have epilepsy, including the most common focal epilepsy, affecting one in 26 American adults.
  • Researchers believe the impact of earlier diagnosis in focal epilepsy patients goes beyond more timely treatment of patients.